Navigation Links
Immtech Receives Listing Notice From NYSE Alternext US
Date:12/30/2008

NEW YORK, Dec. 30 /PRNewswire-FirstCall/ -- Immtech Pharmaceuticals, Inc. (NYSE Alternext US: IMM) announced today that the Company received notice from the NYSE Alternext US (the "Exchange") pertaining to its non-compliance with certain continued listing standards of the Exchange. The Company has the opportunity to submit a plan of compliance to the Exchange by January 23, 2009, and the Company plans to submit such a plan to the Exchange. The stock continues to trade under the symbol "IMM.BC".

Immtech was notified on December 23, 2008 by the Exchange that the Company is not in compliance with the Exchange's requirements under Section 1003(a)(ii), which pertains to having stockholders' equity of not less than $4 million and losses from continuing operations and net losses in three out of its four most recent fiscal years, Section 1003(a)(iii), which pertains to having stockholders' equity of less than $6,000,000 and losses from continuing operations and net losses in its five most recent fiscal years, and Section 1003(a)(iv), which pertains to losses which are substantial in relation to the Company's overall operations or its existing financial resources.

About Immtech Pharmaceuticals, Inc.

Immtech Pharmaceuticals, Inc. and subsidiaries (a development stage enterprise) is focused on global opportunities in the healthcare sector and opportunities in China. Immtech aims to leverage its established expertise and other assets in both new drug sales and enhanced healthcare-related services, including research and information-providing services, for developed and developing countries. For additional information, please visit the Company's website at http://www.immtechpharma.com.

"Safe Harbor" Statement under the Private Securities Reform Act of 1995: Statements in this press release regarding Immtech Pharmaceuticals, Inc.'s business which are not historical facts, are "forward-looking statements" that involve risks and uncertainties. Actual results could differ materially from these forward-looking statements. Factors that could cause or contribute to such differences include, but are not limited to, those discussed under the headings "Management's Discussion and Analysis of Financial Condition and Results of Operations" and "Risk Factors" in Immtech's annual report on Form 10-K for the year ended March 31, 2008 filed on June 18, 2008, and in its other SEC filings and include, but are not limited to: (i) conditions in the credit markets and the general economy; (ii) Immtech's ability to obtain additional funds; (iii) Immtech's ability to manage its remaining resources; (iv) Immtech's ability to continue as a going concern; (v) Immtech's ability to retain key personnel; (vi) the ability of Immtech's scientists and collaborators to discover new compounds; (vii) the availability of additional research grants; (viii) Immtech's ability to obtain regulatory approval of its drug candidates; (ix) the success of Immtech's clinical trials; (x) dependence upon and contractual relationship with partners; (xi) Immtech's ability to protect its intellectual property; and (xii) competition and alternative technologies.

In addition, Immtech does not undertake any obligation, and specifically disclaims any obligation to publicly update or revise forward-looking statements to reflect future events, information or circumstances that arise after the date of this release.


'/>"/>
SOURCE Immtech Pharmaceuticals, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Related medicine news :

1. Immtech Completes Malaria Prevention Trial
2. Immtech Announces Pafuramidine (DB289) Program on Clinical Hold
3. Immtech Investor Conference Call Scheduled for January 3, 2008, at 1 PM
4. Immtech Investor Conference Call Scheduled for February 22, 2008
5. Immtech Announces Update on Business Operations
6. Immtech Announces Results From Hepatitis C Discovery Program
7. Immtech Reports Fiscal Year End 2008 Results
8. Immtech Investor Conference Call Scheduled for June 25, 2008
9. Immtech Reports Fiscal Second Quarter 2009 Results
10. Lake Elsinore Family Caregiver Receives Free Power Wheelchair From The SCOOTER Store
11. DaVita Receives Civil Complaint
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:4/25/2017)... ... , ... Vetoquinol USA® , a world-class developer of ... the EQUISTRO line, at this week’s Rolex Kentucky Three-Day Event in Lexington. Flexadin ... , The scientifically-developed Flexadin UCII supports the body’s normal repair of cartilage and ...
(Date:4/24/2017)... ORLANDO, FLORIDA (PRWEB) , ... April 24, 2017 ... ... of telehealth technology yesterday, featuring Bring Your Own Device (BYOD) capabilities at Telehealth ... compliment LG CNS’ pre-packaged telehealth bundles, which pairs medical devices with a pre-programmed ...
(Date:4/24/2017)... ... 24, 2017 , ... Ridgecrest Herbals makes it a point to lead the ... waste, and support renewable energy. They believe this is a crucial part of their ... for health issues, and maintain that destroying the environment in the pursuit of profit ...
(Date:4/24/2017)... ... April 24, 2017 , ... The bar for just about everything—apparel, ... inhabiting the rarified air of pop and film stardom.(1) Not to be left out ... the smile. Grins now run the gamut from being encrusted with jewels and precious ...
(Date:4/24/2017)... Washington (PRWEB) , ... April 24, 2017 , ... Sean ... OptiGrill, Oxiclean, Space Bag, Sonicare Toothbrush, Juiceman Juicer, and the George Foreman Grill (which ... perhaps any other marketer in the last 25 years. , Now, due to changes ...
Breaking Medicine News(10 mins):
(Date:4/19/2017)... DIEGO , April 19, 2017  Sorrento ... an antibody-centric, clinical-stage biopharmaceutical company developing new treatments ... announced the closing of its previously announced underwritten ... stock at a public offering price of $2.00 ... and estimated offering expenses payable by Sorrento.  The ...
(Date:4/19/2017)... 19, 2017  SARES•REGIS Group leased the first ... at Conejo Spectrum Business Park in ... Biotherapeutics, Inc. , a biopharmaceutical company developing meaningful ... that have been underserved by scientific innovation, with ... cancer, autoimmune and infectious disease. Before ...
(Date:4/18/2017)... -- Research and Markets has announced the addition of ... offering. ... market to grow at a CAGR of 6.35% during the period ... has been prepared based on an in-depth market analysis with inputs ... growth prospects over the coming years. The report also includes a ...
Breaking Medicine Technology: